To gain insight into GBM at the proteomic level, we assembled 39 IDH wild-type GBM samples, along with two IDH mutant GBM and nine low-grade glioma (LGG) samples as a control, from the Samsung Medical Center (SMC) cohort, for which pre-existing whole-exome sequencing (WES) and RNA sequencing (RNA-seq) data already exist19. The gene discussed is IDH1; the disease is low grade glioma.